Baseline characteristics and predictors of outcome in patients with myelodysplastic syndromes living in Western Pennsylvania

References

• Du Y, Fryzek J, Sekeres MA, Taioli E. Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). Leuk Res 2010;34:1–5.
   PubMed Web of Science ®Google Scholar
• Farrow A, Jacobs A, West RR. Myelodysplasia, chemical exposure, and other environmental factors. Leukemia 1989;3:33–35.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008;100:1542–1551.
   PubMed Web of Science ®Google Scholar
• Barzi A, Sekeres MA. Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Cleve Clin J Med 2010;77:37–44.
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008;112:45–52.
   PubMed Web of Science ®Google Scholar
• Morel P, Declercq C, Hebbar M, Bauters F, Fenaux P. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br J Haematol 1996;94:116–119.
   PubMed Web of Science ®Google Scholar
• West RR, Stafford DA, Farrow A, Jacobs A. Occupational and environmental exposures and myelodysplasia: a case-control study. Leuk Res 1995;19:127–139.
   PubMed Web of Science ®Google Scholar
• Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998;83:71–86.
   PubMed Web of Science ®Google Scholar
• Hasle H, Baumann I, Bergstrasser E, et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004;18:2008–2014.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351–1361.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594–7603.
   PubMed Web of Science ®Google Scholar
• Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385–4395.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503–3510.
   PubMed Web of Science ®Google Scholar
• Haase D, Germing U, Schanz J, et al. New and comprehensive cytogenetic prognostication and categorization in MDS. Blood 2006;108(Suppl. 1): Abstract 248.
   PubMed Web of Science ®Google Scholar
• Haase D, Germing U, Schanz J, et al. Evidence for an underestimation of the prognostic impact of poor cytogenetics within the IPSS. Blood 2006;108(Suppl. 1): Abstract 252.
   PubMed Web of Science ®Google Scholar
• Mahesh S, Ginzburg Y, Verma A. Iron overload in myelodysplastic syndromes. Leuk Lymphoma 2008;49:427–438.
   PubMed Web of Science ®Google Scholar
• Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008;83:765–770.
   PubMed Web of Science ®Google Scholar
• Horwich TB, Fonarow GC, Hamilton MA, Maclellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39:1780–1786.
   PubMed Web of Science ®Google Scholar
• Nguyen P. The myelodysplastic syndromes. Hematol Oncol Clin North Am 2009;23:675–691.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Strom SS, Gu Y, Gruschkus SK, Pierce SA, Estey EH. Risk factors of myelodysplastic syndromes: a case-control study. Leukemia 2005;19:1912–1918.
   PubMed Web of Science ®Google Scholar
• Strom SS, Velez-Bravo V, Estey EH. Epidemiology of myelodysplastic syndromes. Semin Hematol 2008;45:8–13.
   PubMed Web of Science ®Google Scholar
• Bjork J, Albin M, Mauritzson N, Stromberg U, Johansson B, Hagmar L. Smoking and myelodysplastic syndromes. Epidemiology 2000;11:285–291.
   PubMed Web of Science ®Google Scholar
• Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008;93:1712–1717.
   PubMed Web of Science ®Google Scholar
• Sperr WR, Wimazal F, Kundi M, et al. Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol 2001;80:272–277.
   PubMed Web of Science ®Google Scholar
• Zhao WL, Xu L, Wu W, et al. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution. Hematol J 2002;3:137–144.
   PubMedGoogle Scholar
• Lee JJ, Kim HJ, Chung IJ, et al. Comparisons of prognostic scoring systems for myelodysplastic syndromes: a Korean multicenter study. Leuk Res 1999;23:425–432.
   PubMed Web of Science ®Google Scholar
• Jacobs RH, Cornbleet MA, Vardiman JW, Larson RA, Le Beau MM, Rowley JD. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 1986;67:1765–1772.
   PubMed Web of Science ®Google Scholar
• Gyger M, Infante-Rivard C, D'Angelo G, Forest L, Lussier P. Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes. Am J Hematol 1988;28:13–20.
   PubMed Web of Science ®Google Scholar
• Tricot G, Boogaerts MA, De Wolf-Peeters C, Van den Berghe H, Verwilghen RL. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. Br J Haematol 1985;59:659–670.
   PubMed Web of Science ®Google Scholar
• Tricot G, Vlietinck R, Boogaerts MA, et al. Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol 1985;60:19–32.
   PubMed Web of Science ®Google Scholar
• Chen BA, Gao C, Ding J, et al. [Analysis on laboratory and clinical characteristics in 65 cases of myelodysplastic syndrome]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009;17: 1472–1476.
   PubMedGoogle Scholar
• Parlier V, van Melle G, Beris P, et al. Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Prognostic significance of morphology and chromosome findings. Cancer Genet Cytogenet 1994;78:219–231.
   PubMed Web of Science ®Google Scholar
• Bernasconi P, Alessandrino EP, Boni M, et al. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. Am J Hematol 1994;46:270–277.
   PubMed Web of Science ®Google Scholar
• Suciu S, Kuse R, Weh HJ, Hossfeld DK. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genet Cytogenet 1990;44:15–26.
   PubMed Web of Science ®Google Scholar
• Morel P, Hebbar M, Lai JL, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993;7:1315–1323.
   PubMed Web of Science ®Google Scholar
• Mirza I, Garzon R, Burns J, Edwards L, Fernandez-Cymering C, Kloss R. Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System. Conn Med 2001;65: 455–463.
   PubMedGoogle Scholar
• Belli C, Acevedo S, Bengio R, et al. Detection of risk groups in myelodysplastic syndromes. A multicenter study. Haematologica 2002;87:9–16.
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010;28:2847–2852.
   PubMed Web of Science ®Google Scholar
• Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 2008;87:691–699.
   PubMed Web of Science ®Google Scholar
• Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest 2009;39:548–553.
   PubMed Web of Science ®Google Scholar